Peregrine Reports Promising Interim Survival Data From Phase II Cotara Recurrent GBM Trial
Peregrine Reports Promising Interim Survival Data From Phase II Cotara Recurrent GBM Trial
TUSTIN, CA–(Marketwire – 05/19/11) – Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM – News ), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced interim median overall survival of 8.8 months (38 weeks, 40 patients at first relapse) from a Phase II trial for Cotara in recurrent glioblastoma …
Read more on Marketwire via Yahoo! Finance
Categories: Breast Cancer Information Tags: Cotara, Data, From, Interim, Peregrine, Phase, Promising, recurrent, Reports, Survival, Trial
GTx Provides Corporate Update and Reports 2010 Financial Results
GTx Provides Corporate Update and Reports 2010 Financial Results
MEMPHIS, Tenn.–(BUSINESS WIRE)–GTx provides a corporate update and announces fourth quarter and full year 2010 financial results.
Read more on Business Wire
Categories: Breast Cancer Information Tags: 2010, Corporate, financial, Provides, Reports, Results, Update
TELUS Reports Fourth Quarter 2010 Results
TELUS Reports Fourth Quarter 2010 Results
EPS grows 43 per cent, EBITDA up 7 per cent, free cash flow increases Results driven by growth in wireless subs, ARPU, high-speed Internet, record TV additions VANCOUVER , Feb. 11 /PRNewswire-FirstCall/ – TELUS Corporation reported fourth quarter 2010 revenue of $2.55 billion , an increase of more than four per cent. This increase was generated by nine per cent growth in wireless revenue and …
Read more on redOrbit
Exelixis Reports Promising Interim Data From Patients With Ovarian Cancer Treated With XL184
Exelixis Reports Promising Interim Data From Patients With Ovarian Cancer Treated With XL184
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (NASDAQ:EXEL) today reported interim data from the cohort of patients with advanced epithelial ovarian cancer, primary peritoneal, or fallopian tube carcinoma treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT). Ignace Vergote, M.D., Ph.D., Head of the Department of Obstetrics and Gynaecology and …
Read more on Business Wire
Categories: Metastatic Breast Cancer Tags: cancer, Data, Exelixis, From, Interim, Ovarian, Patients, Promising, Reports, Treated, XL184
Myriad Genetics Reports Fiscal 2011 First Quarter Financial Results
Myriad Genetics Reports Fiscal 2011 First Quarter Financial Results
SALT LAKE CITY — Myriad Genetics, Inc. , a leading molecular diagnostic company, today reported financial results for its first fiscal quarter ended September 30, 2010.
Read more on GlobeNewswire via Yahoo! Finance
Categories: Breast Cancer Information Tags: 2011, financial, first, Fiscal, Genetics, Myriad, Quarter, Reports, Results
Genetic Disease Test Reports ? Should You Get One
Over the course of the past decade, broad new understandings have been acquired into genetic predispositions to a number of diseases. The fact is, that some people are born with a higher risk factor to some diseases then others. With this new knowledge new test methods have been developed to determine just who these people are.
The Choice is Yours
What this means is that you can now take a test to see if you are more vulnerable to such diseases as breast cancer than the person sitting next to you. So now the question is, should you take one of these expensive complex tests and if so, what will you do with the information that is contained in you test report?
Expensive and Vague
These comprehensive genetic profile test reports cost an average of around $1500 – $2000 and cover a number of diseases. However; they don’t offer precise probabilities. That is, they can’t tell you if you are going to or not going to come down with any of the diseases that they profile. They only tell you if you have a higher or lower probability of contacting them as compared to the population as a whole.
Is it Safe for You to Smoke Cigarettes?
Wouldn’t it be ironic if you drove to the lab, picked up your test report, read that you were at the lowest probability for all the diseases listed and were killed in a car wreck on your way home? On the other hand if your test report determined that you were at a low risk for lung cancer, does this mean that it is safe for you to smoke?
Test Report or Vacation the Choice is Yours
So the argument goes on, while the test reports keep being compiled. However; as one prominent doctor recently put it. If you care enough about your health to shell out $2000 for one of these reports, why not take that $2000 and go out and take a great vacation, because that will have a far greater positive impact on your general overall health.
OhioHealth Reports More Young Women Are Getting Mammograms
WBNS-10TV Anchor Heather Pick’s public battle and death from breast cancer raised the awareness among younger women of the importance of mammograms. OhioHealth Hospitals are happy to report that more women are getting routine mammograms.
Categories: Breast Cancer Mammogram Tags: getting, Mammograms, more, OhioHealth, Reports, women, Young
TELUS Reports Second Quarter 2010 Results
TELUS Reports Second Quarter 2010 Results
Strong growth in net income of 21% and free cash flow of 67% Improving wireless trends in ARPU, subscriber additions and churn TELUS TV additions of 29,000 lead to doubling of subscriber base in last year VANCOUVER, Aug. 6 /PRNewswire-FirstCall/ – TELUS Corporation reported second quarter 2010 revenue of $2.4 billion, an increase of one per cent, as continued growth in wireless revenues and …
Read more on redOrbit
GTx, Inc. Reports Second Quarter 2010 Corporate Results
GTx, Inc. Reports Second Quarter 2010 Corporate Results
MEMPHIS, Tenn.–(BUSINESS WIRE)–GTx, Inc. (Nasdaq: GTXI) today reported financial results for the second quarter of 2010. The net loss for the quarter ended June 30, 2010 was $12.9 million compared with a net loss of $11.3 million for the quarter ended June 30, 2009. The net loss for the second quarter of 2010 included a $1.7 million non-cash impairment charge related to the conclusion of the …
Read more on Business Wire
Categories: Breast Cancer Information Tags: 2010, Corporate, Inc., Quarter, Reports, Results, second
Enzon Reports Second Quarter 2010 Results
Enzon Reports Second Quarter 2010 Results
BRIDGEWATER, N.J.–(BUSINESS WIRE)–Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced its financial results for the second quarter of 2010. For the second quarter of 2010, Enzon reported a loss from continuing operations of $5.4 million or $0.09 per diluted share, as compared to a loss of $19.7 million or $0.43 per diluted share for the second quarter of 2009. “Enzon made significant …
Read more on Business Wire